Alzheimer's drug proves effective in slowing symptoms, says Eisai

Japanese drug maker Eisai Co. said Wednesday that its Alzheimer's disease drug, under development with U.S. firm Biogen Inc., has succeeded in slowing the aggravation of symptoms in a clinical trial, potentially paving the way for patients to treat the disease more effectively.The new drug, lecanemab, removes a type of protein called amyloid beta, considered the cause of the disease. The protein accumulates inside the brain and destroys nerve cells, according to Eisai.The company said it aims to win approval for the drug in Japan, the United States and Europe in 2023. The U.S. Food and Drug…READ FULL ARTICLE